

TRAUMATIC BRAIN INJURY (TBI) RESEARCH & DEVELOPMENT



Pioneering Brain Health Research

Geneva advances brain health research to tackle one of military medicine's most urgent challenges: traumatic brain injury (TBI). From rapid diagnostics to long-term recovery, our work spans the full continuum of care - advancing early intervention, advanced therapies, and cognitive restoration to improve outcomes, readiness, and quality of life for service members.

The Geneva Advantage

With deep DoD expertise and agile infrastructure, Geneva accelerates innovation by guiding promising ideas through complex regulatory, operational, and contracting pathways—transforming research into deployable solutions.

➤ Mission-Aligned Expertise

Proven track record executing DoD-prioritized, operational research for service members

➤ End-to-End Support

From proposal to dissemination, we manage every step

➤ Strategic Access

Embedded at military sites with direct reach to service members and multidisciplinary partners

➤ Accelerated Impact

Advancing research to field-ready solutions through agile, cross-sector partnerships

CONNECT
WITH US



253.383.1398



genevaUSA.org

Data represents 1 January 2024 - 1 June 2025

Mission Metrics

Active Funds Managed in 2024

\$19.7M

Active Research Projects

14

Principal Investigators

9

Research Sites

16

Critical Areas of Innovation

Rapid Diagnostics

Portable tools for early detection

Blast Impact

Effects of repeated blast exposure

Biomarkers & Mechanisms

Indicators and causes of brain trauma

Neurotechnology

Tools for cognitive recovery

Targeted Treatments

Therapies to restore brain function

Advanced Screening

Improved detection methods

Standardized Care

Guidelines from injury to recovery

Concussion Collaboration

Joint research on long-term effects



Leading the Frontlines of Research — Project Spotlights

Advancing Brain Health Solutions for the Warfighter

Geneva is a key collaborator for the Department of Defense's Warfighter Brain Health Initiative, a multi-year effort to accelerate medical solutions that prevent, detect, and treat brain injuries across operational environments. Issued through the U.S. Army Medical Materiel Development Agency, the project takes an integrated approach to advancing prototypes that address traumatic brain injury (TBI) and behavioral health, beginning with the development of field-ready TBI capabilities.

Impact

This initiative enhances military readiness by fostering rapid innovation in brain health technologies, enabling early intervention, improved outcomes, and long-term cognitive resilience for service members.

Innovative Immune-Based Therapy for Trauma and TBI

Geneva supports the development of a novel treatment targeting the body's immune response to traumatic brain injury (TBI) and hemorrhagic shock (THS). This approach leverages Nomacopan, a protein originally derived from tick saliva, to reduce inflammation, improve survival, and protect against organ damage. Designed for intramuscular injection, the therapy is being evaluated for use in prolonged field care where rapid, low-complexity interventions are essential.

Impact

This research advances a groundbreaking immune-modulating therapy with the potential to improve trauma outcomes on the battlefield and beyond, enhancing survivability for warfighters and informing future civilian emergency care.

Together, We're Redefining What's Possible in Traumatic Brain Injury

Whether you're a researcher, policymaker, or industry innovator, Geneva brings the expertise, infrastructure, and partnerships needed to deliver results where they matter most—on the front lines of defense health.

Let's develop battlefield-ready solutions that save lives and shape the future of TBI care.

Learn more about Geneva's
TBI research:

